International Ototoxicity Management Working Group

IOMG

Source/Copyright: OSHA

Focus Area: AMG

management in

patients treated with

aminoglycoside

antibiotics

<u>Subgroup</u>

Cystic fibrosis (CF)

Patients with cystic fibrosis (CF) who are treated with aminoglycosides are more likely to develop hearing loss, tinnitus and/or balance problems than Auditory and vestibular those who do not receive aminoglycoside treatment.

> Should CF patients be monitored for hearing loss, tinnitus and/or balance problems?

Leads

- Angela Garinis garinis@ohsu.edu
- Carmen Brewer brewerc@nidcd.nih.gov
 - Gayla Poling Poling.gayla@mayo.edu

Reference:

Garinis AC, Cross CP, Srikanth P, Carroll K, Feeney MP, Keefe DH, Hunter LL, Putterman DB, Cohen DM, Gold JA, Stevger PS. (2017). The cumulative effects of intravenous antibiotic treatments on hearing in patients with cystic fibrosis. J Cyst Fibros, 16(3):401-409. doi: 10.1016/j.jcf.2017.01.006

IOMG Deliverables:

Collate/review existing recommendations

- Work with patients and providers to develop recommendations for applying audiology practice guidelines for ototoxicity management in cystic fibrosis patients
- Submit this consensus document for publication Survey patients and providers regarding the acceptance and utility of recommendations